692764-05-9

Upstream product

• 87-13-8 diethyl 2-ethoxymethylenemalonate 
• 139-59-3 4-phenoxyanilin 
• 104007-15-0 diethyl 2-[(4-phenoxyphenylamino)methylidene]malonate 

Downstream Products

• 35975-94-1 4-hydroxy-6-phenoxy-quinoline-3-carboxylic acid 
• 769952-75-2 4-chloro-6-phenoxy-quinoline 
• 1141925-64-5 C₁₈H₁₆N₂O₄ 
• 1337542-93-4 4-amino-6-phenoxyquinoline-3-carboxylic acid 
• 1337542-94-5 ethyl 4-amino-6-phenoxyquinoline-3-carboxylate 
• 1337542-95-6 ethyl 4-chloro-6-phenoxyquinoline-3-carboxylate 
• 57278-51-0 4-oxo-6-phenoxy-1,4-dihydro-quinoline-3-carboxylic acid 
• 855871-94-2 6-phenoxy-quinolin-4-ol 
• 931127-30-9 4-(β-O-tetraacetyl-D-glucosyloxy)-6-phenoxyquinoline 

Relevant academic research and scientific papers

METHOD OF IMPROVING STABILITY OF SWEET ENHANCER AND COMPOSITION CONTAINING STABILIZED SWEET ENHANCER

The present invention includes methods of stabilizing one or more sweet enhancers when they are exposed to a light source as well as liquid compositions containing one or more sweet enhancers and one or more photostabilizers.

METHOD OF IMPROVING STABILITY OF SWEET ENHANCER AND COMPOSITION CONTAINING STABILIZED SWEET ENHANCER

The present invention includes methods of stabilizing one or more sweet enhancers when they are exposed to a light source as well as liquid compositions containing one or more sweet enhancers and one or more photostabilizers.

SWEET FLAVOR MODIFIER

The present invention includes compounds having structural formula (I), or pharmaceutically acceptable salts, solvate, and/or ester thereof. These compounds are useful as sweet flavor modifiers. The present invention also includes compositions comprising the present compounds and methods of enhancing the sweet taste of ingestible compositions. Furthermore, the present invention provides methods for preparing the compounds.

Design, synthesis, and biological evaluation of novel quinoline derivatives as HIV-1 Tat-TAR interaction inhibitors

Thirty-two quinoline derivatives were designed and synthesized as HIV-1 Tat-TAR interaction inhibitors. All the compounds showed high antiviral activities in inhibiting the formation of SIV-induced syncytium in CEM174 cells. Nine of them with low cytotoxicities were evaluated by Tat dependent HIV-1 LTR-driven CAT gene expression colorimetric enzyme assay in human 293T cells, indicating effective inhibitory activities of blocking the Tat-TAR interaction. Molecular modeling experiments indicated that these compounds may inhibit Tat-TAR interaction by binding to Tat protein instead of TAR RNA.

ANTIMICROBIAL COMPOUNDS BASED UPON 4-AMINOQUINOLINE

There is provided compounds of formula I wherein R1, R2, R3, R4, X1, X2 and A have meanings given in the description. Also provided are medical uses of such compounds, such as the killing c

Preparation of quinoline hexose analogs as novel chloroquine-resistant malaria treatments (1). Synthesis of 4-hydroxyquinoline-β-glucosides

Quinoline hexose analogs are expected to be useful as novel agents for treatment of chloroquine-resistant malaria. Here, we report preparation of 4-hydroxy quinoline-β-glucosides from anilines in 4 steps.

Evaluation of 3-carboxy-4(1H)-quinolones as inhibitors of human protein kinase CK2

Due to the emerging role of protein kinase CK2 as a molecule that participates not only in the development of some cancers but also in viral infections and inflammatory failures, small organic inhibitors of CK2, besides application in scientific research, may have therapeutic significance. In this paper, we present a new class of CK2 inhibitors-3-carboxy-4(1H)-quinolones. This class of inhibitors has been selected via receptor-based virtual screening of the Otava compound library. It was revealed that the most active compounds, 5,6,8-trichloro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid (7) (IC 50 = 0.3 μM) and 4-oxo-1,4-dihydrobenzo[h]quinoline-3-carboxylic acid (9) (IC50 = 1 μM), are ATP competitive (Ki values are 0.06 and 0.28 μM, respectively). Evaluation of the inhibitors on seven protein kinases shows considerable selectivity toward CK2. According to theoretical calculations and experimental data, a structural model describing the key features of 3-carboxy-4(1H)-quinolones responsible for tight binding to CK2 active site has been developed.